I think it is interesting how the FDA divided up the levels of covid severity and is using that to decide how to evaluate drug candidates. I think we knew early on that Covid has a wide range of effect on people and most drugs can possibly help in some of those stages and not others. I think the FDA is trying to find treatments that might not help in most cases but might help in a specific stage as to not rule out any options.

It could simply mean that the FDA wanted to see if Leronlimab might work in severe cases only and moderate not at all, for example. The potential that Leronlimab is helping any level of symptoms is basically just being discovered and Leronlimab is very unique in that regard. The design of the trials and # of patients etc.. might really be un-important, The FDA might look ate all the data as it sits for each patient no matter what trial it is in and have a good idea of how to approve based on what Leronlimab actually does, rather than how it fit into a trial protocal. There is no doubt in my mind that Leronlimab is shaping how Covid is understood more than anything else, which is backwards from the normal process. Normally they study the disease and then find a drug, for Leronlimab it is study what Leronlimab is doing and we now know the disease.